{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:27:29Z","timestamp":1791851249248,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jhep.2015.08.010","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T06:46:29Z","timestamp":1440053189000},"page":"1511-1522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Management of direct-acting antiviral agent failures"],"prefix":"10.1016","volume":"63","author":[{"given":"Maria","family":"Buti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Riveiro-Barciela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.08.010_b0005","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0015","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.08.010_b0020","first-page":"S219","article-title":"Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort","volume":"60","author":"Jensen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0025","first-page":"S672","article-title":"Efficacy of sofosbuvir and simeprevir-based regimens for 304 HCV treatment-experienced patients in a reallife setting; data from the TRIO network","volume":"60","author":"Bacon","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0030","doi-asserted-by":"crossref","first-page":"S621","DOI":"10.1016\/S0168-8278(15)30978-8","article-title":"Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +\/\u2212 simeprevir in the TRIO network: academic and community treatment of a real-world, heterogeneous population","volume":"62","author":"Dieterich","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0035","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/S0168-8278(15)30014-3","article-title":"All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-TARGET real world experience","volume":"62","author":"Reddy","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0040","doi-asserted-by":"crossref","first-page":"S622","DOI":"10.1016\/S0168-8278(15)30980-6","article-title":"Sofosbuvir-based treatment under real life conditions in Germany (The SOFGER trial)","volume":"62","author":"Buggisch","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0045","first-page":"S660","article-title":"Safety and efficacy of sofosbuvir (SOF) in combination with simeprevir (SIM)+ribavirin (RBV) in patients with genotype 1: interim results of a prospective, observational study","volume":"60","author":"Sulkowski","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0050","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/S0168-8278(15)30149-5","article-title":"Safety and efficacy of the combination Daclatasvir-Sofosbuvir in HCV genotype 1-mono-infected patients from the French observational cohort ANRS CO22 HEPATHER\u2217","volume":"62","author":"Pol","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0055","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1016\/S0168-8278(15)30162-8","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-word experience from HCV-TARGET","volume":"62","author":"Saxena","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0060","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1016\/S0168-8278(15)30186-0","article-title":"Real-world effectiveness of ledipasvir\/sofosbuvir 8weeks chronic hepatitis C treatment","volume":"62","author":"Buggisch","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0065","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0070","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0075","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0080","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/S0168-8278(15)30151-3","article-title":"Sofosbuvir+PegInterferon\/Ribavirin for 12 weeks vs Sofosbuvir+Ribavirin for 16 or 24weeks in Genotype 3 HCV infected patients and treatment-experienced cirrhotic pacientes with genotype 2 HCV: the BOSON study","volume":"62","author":"Foster","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0085","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0090","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0095","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0100","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0105","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0110","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.08.010_b0115","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/j.gastro.2013.11.047","article-title":"Telaprevir twice daily is noninferior to telaprevir every 8hours for patients with chronic hepatitis C","volume":"146","author":"Buti","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.08.010_b0120","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2014.06.005","article-title":"Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program","volume":"61","author":"Colombo","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0125","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jvh.12347","article-title":"Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study","volume":"21","author":"Dierynck","year":"2014","journal-title":"J Viral Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1371\/journal.pone.0034372","article-title":"Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials","volume":"7","author":"Kieffer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.08.010_b0135","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.21781","article-title":"Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients","volume":"46","author":"Kieffer","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0140","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0145","first-page":"387","article-title":"Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial","volume":"18","author":"Ogert","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.08.010_b0150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2013.06.029","article-title":"Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies","volume":"444","author":"Barnard","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2015.08.010_b0155","first-page":"00881","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","volume":"28","author":"Lenz","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0160","unstructured":"Verbinnen T, Fevery B, Vijgen L, Picchio G, De Meyer S, Lenz O. Phenotypic characterisation of genotype 1 hepatitis C NS3 protease variants from clinical studies with simeprevir. In: Presented at the international workshop on antiviral drug resistance, Berlin, Germany; 2014"},{"key":"10.1016\/j.jhep.2015.08.010_b0165","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.08.010_b0170","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.08.010_b0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2015.08.010_b0180","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/infdis\/jiu613","article-title":"Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism","volume":"211","author":"McCloskey","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2015.08.010_b0185","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0190","first-page":"S679","article-title":"Long-term follow-up analysis of RAVs in HCV NS3, NS5A and NS5B in DAA therapy failure patients","volume":"62","author":"Susser","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0195","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial","volume":"13","author":"Lawitz","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2015.08.010_b0200","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJMc1307641","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"369","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0205","first-page":"S672","article-title":"Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population","volume":"60","author":"Bacon","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0210","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.08.010_b0215","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S0168-8278(15)30168-9","article-title":"A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-na\u00efve and experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1","volume":"62","author":"Kwo","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0220","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/S0168-8278(15)30158-6","article-title":"A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12weeks of Simeprevir (SMV) plus Sofosbuvir (SOF) in treatment-na\u00efve or experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2","volume":"62","author":"Lawitz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0225","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0230","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0235","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0240","first-page":"1128A","article-title":"baseline and post-baseline resistance analyses of phase 2\/3 studies of ledipasvir\/sofosbuvir\u00b1RBV","volume":"60","author":"Sarrazin","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0245","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27826","article-title":"Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis","author":"Reddy","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0250","doi-asserted-by":"crossref","first-page":"S658","DOI":"10.1016\/S0168-8278(15)31112-0","article-title":"Analysis of natural resistance profile to NS5A replication complex inhibitors in different hepatitis C genotypes","volume":"62","author":"Bagaglio","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0255","doi-asserted-by":"crossref","first-page":"S679","DOI":"10.1016\/S0168-8278(15)31097-7","article-title":"Prevalence of pre-treatment NS5A and NS5B resistance associated variants and genetic variation within HCV subtypes across different countries","volume":"62","author":"Svarovskaia","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0260","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3851\/IMP2763","article-title":"Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1\u20134","volume":"20","author":"McCormick","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.08.010_b0265","doi-asserted-by":"crossref","first-page":"S681","DOI":"10.1016\/S0168-8278(15)31103-X","article-title":"Consideration of viral resistance for optimization of direct antiviral therapy of chronic hepatitis C","volume":"62","author":"Dietz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0270","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/S0168-8278(15)30073-8","article-title":"Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor Ledipasvir","volume":"62","author":"Dvory-Sobol","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0275","first-page":"218A","article-title":"L159F and V321A sofosbuvir treatment-emergent HCV NS5B substitutions","volume":"60","author":"Svarovskaia","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0280","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0285","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0168-8278(15)30155-0","article-title":"Daclatasvir plus Sofosbuvir for treatment of HCV genotypes 1\u20134 in HIV-HCV coinfection: the ALLY-2 study","volume":"62","author":"Wyles","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0420","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0295","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.08.010_b0300","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0305","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0310","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.08.010_b0315","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/S0168-8278(15)30071-4","article-title":"Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with Paritaprevir\/r-, Ombitasvir- and Dasabuvir-based regimens","volume":"62","author":"Krishnan","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0320","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.08.010_b0325","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"Donaldson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0330","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/135965350000500203","article-title":"Hepatitis C virus kinetics","volume":"5","author":"Herrmann","year":"2000","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.08.010_b0335","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.7041255","article-title":"Rapid evolution of RNA genomes","volume":"215","author":"Holland","year":"1982","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.jhep.2015.08.010_b0340","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/JVI.66.5.3225-3229.1992","article-title":"Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution","volume":"66","author":"Martell","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2015.08.010_b0345","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1099\/0022-1317-81-7-1631","article-title":"Replication of hepatitis C virus","volume":"81","author":"Bartenschlager","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2015.08.010_b0350","doi-asserted-by":"crossref","first-page":"e83361","DOI":"10.1371\/journal.pone.0083361","article-title":"Ultra-deep pyrosequencing (UDPS) data treatment to study amplicon HCV minor variants","volume":"8","author":"Gregori","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.08.010_b0355","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bpg.2012.09.011","article-title":"The role of resistance in HCV treatment","volume":"26","author":"Vermehren","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2015.08.010_b0360","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature04388","article-title":"Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population","volume":"439","author":"Vignuzzi","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2015.08.010_b0365","first-page":"A78","article-title":"Validation of HIV-1 drug resistance testing by deep sequencing: insights from comparative Sanger sequencing","volume":"19","author":"Thielen","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.08.010_b0370","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/j.gastro.2015.01.002","article-title":"Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014","volume":"148","author":"Pawlotsky","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.08.010_b0375","doi-asserted-by":"crossref","first-page":"S620","DOI":"10.1016\/S0168-8278(15)30976-4","article-title":"The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir\/sofosbuvir +\/\u2212 RBV","volume":"62","author":"Sarrazin","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0380","doi-asserted-by":"crossref","first-page":"S677","DOI":"10.1016\/S0168-8278(15)31094-1","article-title":"Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with Grazoprevir\/Elbasvir +\/\u2212 Ribavirin: the C-WORTHY study","volume":"62","author":"Black","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0385","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bourliere","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2015.08.010_b0390","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"Hezode","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.08.010_b0425","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","article-title":"Grazoprevir\/Elbasvir plus Ribavirin For chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent","volume":"63","author":"Forns","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0400","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/hep.27814","article-title":"Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens","volume":"61","author":"Wyles","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.08.010_b0405","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(14)60010-6","article-title":"Successful retreatment with Sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior Sofosbuvir plus Ribavirin therapy","volume":"60","author":"Esteban","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0410","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/S0168-8278(15)30012-X","article-title":"Retreatment fo patients who failed 8 or 12weeks of ledipasvir\/sofosbuvir-based regimens with ledipasvir\/sofosbuvir for 24weeks","volume":"62","author":"Lawitz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.08.010_b0415","unstructured":"Hezode C, Chevaliez S, Scoazec G, Soulier A, Bouvier-Alias M, Ruiz I, et al. Retreatment with an interferon-free combination of Simeprevir-Sofosbuvir in patients who had previously failed on HCV NS5A inhibitor based regimen. In: 13th European meeting on HIV & hepatitis \u2013 treatment strategies & antiviral drug resistance, Barcelona, Spain; 2015."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815005528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815005528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T17:59:51Z","timestamp":1653069591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815005528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0168827815005528"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.08.010","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of direct-acting antiviral agent failures","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association for the Study of the Liver. Published by Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}